AC Immune (NASDAQ:ACIU) Short Interest Up 94.4% in December

AC Immune (NASDAQ:ACIU) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 3,593,227 shares, an increase of 94.4% from the November 30th total of 1,848,164 shares. Based on an average trading volume of 2,209,361 shares, the short-interest ratio is currently 1.6 days. Currently, 3.8% of the shares of the company are sold short. Currently, 3.8% of the shares of the company are sold short. Based on an average trading volume of 2,209,361 shares, the short-interest ratio is currently 1.6 days.

Analyst Ratings Changes

Several brokerages have recently issued reports on ACIU. BTIG Research restated a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research note on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AC Immune in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded shares of AC Immune from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 9th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $10.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Private Advisor Group LLC purchased a new stake in AC Immune during the 3rd quarter worth about $48,000. Sei Investments Co. acquired a new stake in shares of AC Immune during the 2nd quarter worth about $51,000. Susquehanna International Group LLP purchased a new stake in shares of AC Immune during the 3rd quarter worth approximately $63,000. Assenagon Asset Management S.A. acquired a new position in AC Immune in the third quarter valued at $549,000. Finally, Acadian Asset Management LLC increased its holdings in shares of AC Immune by 87.1% in the 1st quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after acquiring an additional 172,796 shares during the period. 51.36% of the stock is owned by institutional investors and hedge funds.

AC Immune Price Performance

Shares of NASDAQ ACIU opened at $3.13 on Friday. AC Immune has a 52-week low of $1.43 and a 52-week high of $4.00. The business’s 50 day moving average is $3.10 and its two-hundred day moving average is $2.62. The firm has a market cap of $314.28 million, a price-to-earnings ratio of -3.73 and a beta of 1.60.

AC Immune (NASDAQ:ACIU) last announced its earnings results on Tuesday, November 4th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. The company had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $0.81 million. AC Immune had a negative return on equity of 84.32% and a negative net margin of 1,642.89%. Analysts anticipate that AC Immune will post -0.62 EPS for the current fiscal year.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.